OR WAIT 15 SECS
ANA will use Quotient’s formulation and manufacturing knowledge to develop and supply the drug product for clinical trials by the third quarter of 2020.
ANA Therapeutics, a biotech startup, and Quotient Sciences, a drug development and manufacturing solutions company, announced on August 11, 2020 that they are collaborating on the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), for the potential treatment of COVID-19.
Under the terms of the agreement, Quotient will scale up the capsule formulation, and characterize and optimize the manufacturing process of the drug candidate through to clinical trials using its facility in Garnet Valley, PA, according to a Quotient press release. ANA will use Quotient’s formulation and manufacturing knowledge to develop and supply the drug product for clinical trials by the third quarter of 2020.
“We have selected Quotient Sciences as our development and manufacturing partner and our plan is simple,” said Andrew Bartynski, chief operation officer, ANA Therapeutics, in the press release. “Niclosamide has the potential to be an effective antiviral agent to combat COVID-19, and our top goal is to complete a clinical trial to determine its efficacy in treating patients with COVID-19. Quotient’s speed and agility will play a key role in reaching that important milestone.”
“We are proud to partner with ANA Therapeutics in their pursuit of a treatment to fight this coronavirus pandemic,” added Mark Egerton, PhD, CEO of Quotient Sciences, in the press release. “Our experience and flexible manufacturing approaches will enable ANA Therapeutics to initiate clinical testing in an accelerated timeframe.”